| Liraglutide as Additional Treatment in Type 1 Diabetes. | |
| | |
MedLine Citation:
|
PMID: 21646283 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Objective. To determine whether the addition of liraglutide to insulin in patients with type 1 diabetes leads to an improvement in glycemic control and diminished glycemic variability. Subjects and Methods. Fourteen patients with well controlled type1 diabetes on continuous glucose monitoring and intensive insulin therapy were treated with liraglutide for one week. 8 patients continued therapy for 24 weeks. Results. In all fourteen patients, mean fasting and mean weekly glucose concentrations decreased significantly after one week from 130 ±10 mg/dl to 110± 8 mg/dl (p <0.01) and from 137.5±20 to 115±12 mg/dl (p < 0.01) respectively. Glycemic excursions also improved significantly at one week. The mean S.D. of glucose concentrations decreased from 56±10 to 26±6 mg/dl (p<0.01) and the CV decreased from 39.6±10 to 22.6±7 (p<0.01). There was a concomitant fall in the basal insulin from 24.5±6 units to 16.5± 6 units (p<0.01) and of bolus insulin from 22.5±4 units to 15.5± 4 units (p<0.01). In patients who continued therapy with liraglutide for 24 weeks, mean fasting, mean weekly glucose concentrations, glycemic excursions, basal and bolus insulin dose also decreased significantly (p<0.01). HbA1c decreased significantly at 24 weeks from 6.5% to 6.1% (p=0.02), as did the body weight by 4.5±1.5 Kg (p=0.02). Conclusion. Liraglutide treatment provides an additional strategy for improving glycemic control in type 1 diabetes. It also leads to weight loss. |
| | |
Authors:
|
Ajay Varanasi; Natalie Bellini; Deepti Rawal; Mehul Vora; Antoine Makdissi; Sandeep Dhindsa; Ajay Chaudhuri; Paresh Dandona |
Related Documents
:
|
8492723 - Hypersecretion of amylin from the perfused pancreas of genetically obese (fa/fa) rats a... 16430493 - Characterization of obesity in japanese monkeys (macaca fuscata) in a pedigreed colony. 22056373 - Da-1229, a novel and potent dpp4 inhibitor, improves insulin resistance and delays the ... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-6-6 |
Journal Detail:
|
Title: European journal of endocrinology / European Federation of Endocrine Societies Volume: - ISSN: 1479-683X ISO Abbreviation: - Publication Date: 2011 Jun |
Date Detail:
|
Created Date: 2011-6-7 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9423848 Medline TA: Eur J Endocrinol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
A Varanasi, Division of Endocrinology, Diabetes and Metabolism, State University of New York at Buffalo and Kaleida Health, Buffalo, United States. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Free radical scavenging (DPPH) potential in nine Mentha species.
Next Document: RELATIONSHIP OF CYP21A2 GENOTYPE AND SERUM 17-HYDROXYPROGESTERONE AND CORTISOL LEVELS IN A LARGE COH...